News|Articles|April 4, 2024

Increasing Legislative Changes May Mark Turning Point in US Biosimilar Adoption

Clinicians advocate for an at-parity approach to biosimilars, in which they, their patients, and the local market would have the freedom to choose the product that best suits their needs.

One of the most recurrent themes within the biosimilar industry revolves around the continued approval and introduction of adalimumab (Humira) biosimilars. Presently, despite the availability of 10 adalimumab biosimilars in the market, they collectively hold less than 2% market share, although most are priced substantially lower than the reference product.¹

Related to this article

November 9th, 2026

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.

November 9th, 2026

What’s New in the 2027 GOLD Report for COPD

The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.

November 8th, 2026

Elebsiran Plus Tobevibart Suppresses HDV RNA in Phase 3 ECLIPSE 1 Trial

Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.

November 8th, 2026

Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil

Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.

November 8th, 2026

Pemvidutide Improves Multiple MASH Fibrosis Markers at 48 Weeks

In the phase 2b IMPACT trial, up to 42.9% of patients with MASH achieved concurrent liver fat, ALT, and stiffness responses on pemvidutide vs 3.3% on placebo.

November 8th, 2026

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.